The neurobiology of cognition in schizophrenia

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Currently, no drugs exist that effectively treat cognition in people with schizophrenia. What is known about the neurobiology of cognition in schizophrenia is derived from the animal literature; it is inadequate and superficial. Despite this lack, pharmacologic research into potential molecular targets has uncovered several viable possibilities from animal studies. A subcommittee of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program investigated the range of putative molecular targets for treating cognition. Those targets that show promise for pharmacologic focus include the dopamine receptors (especially D1) in the prefrontal cortex (PFC), the serotonin receptors in the PFC and anterior cingulate cortex, the glutamatergic excitatory synapse, the acetylcholine nicotinic receptors in the hippocampus, the acetylcholine muscarinic receptors, and the brain γ-aminobutyric acid (GABA) system. Once developed and tested, the effective compounds will be valuable for the treatment of the symptom domains of cognitive dysfunction and negative symptoms.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalJournal of Clinical Psychiatry
Volume67
Issue numberSUPPL. 9
StatePublished - 2006

Fingerprint

Neurobiology
Cognition
Schizophrenia
Prefrontal Cortex
Aminobutyrates
Dopamine D1 Receptors
Serotonin Receptors
Gyrus Cinguli
Nicotinic Receptors
Muscarinic Receptors
Research
Synapses
gamma-Aminobutyric Acid
Hippocampus
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

The neurobiology of cognition in schizophrenia. / Tamminga, Carol A.

In: Journal of Clinical Psychiatry, Vol. 67, No. SUPPL. 9, 2006, p. 9-13.

Research output: Contribution to journalArticle

@article{3f0b21d0313b458eb7fe18b05ad82e08,
title = "The neurobiology of cognition in schizophrenia",
abstract = "Currently, no drugs exist that effectively treat cognition in people with schizophrenia. What is known about the neurobiology of cognition in schizophrenia is derived from the animal literature; it is inadequate and superficial. Despite this lack, pharmacologic research into potential molecular targets has uncovered several viable possibilities from animal studies. A subcommittee of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program investigated the range of putative molecular targets for treating cognition. Those targets that show promise for pharmacologic focus include the dopamine receptors (especially D1) in the prefrontal cortex (PFC), the serotonin receptors in the PFC and anterior cingulate cortex, the glutamatergic excitatory synapse, the acetylcholine nicotinic receptors in the hippocampus, the acetylcholine muscarinic receptors, and the brain γ-aminobutyric acid (GABA) system. Once developed and tested, the effective compounds will be valuable for the treatment of the symptom domains of cognitive dysfunction and negative symptoms.",
author = "Tamminga, {Carol A.}",
year = "2006",
language = "English (US)",
volume = "67",
pages = "9--13",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 9",

}

TY - JOUR

T1 - The neurobiology of cognition in schizophrenia

AU - Tamminga, Carol A.

PY - 2006

Y1 - 2006

N2 - Currently, no drugs exist that effectively treat cognition in people with schizophrenia. What is known about the neurobiology of cognition in schizophrenia is derived from the animal literature; it is inadequate and superficial. Despite this lack, pharmacologic research into potential molecular targets has uncovered several viable possibilities from animal studies. A subcommittee of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program investigated the range of putative molecular targets for treating cognition. Those targets that show promise for pharmacologic focus include the dopamine receptors (especially D1) in the prefrontal cortex (PFC), the serotonin receptors in the PFC and anterior cingulate cortex, the glutamatergic excitatory synapse, the acetylcholine nicotinic receptors in the hippocampus, the acetylcholine muscarinic receptors, and the brain γ-aminobutyric acid (GABA) system. Once developed and tested, the effective compounds will be valuable for the treatment of the symptom domains of cognitive dysfunction and negative symptoms.

AB - Currently, no drugs exist that effectively treat cognition in people with schizophrenia. What is known about the neurobiology of cognition in schizophrenia is derived from the animal literature; it is inadequate and superficial. Despite this lack, pharmacologic research into potential molecular targets has uncovered several viable possibilities from animal studies. A subcommittee of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program investigated the range of putative molecular targets for treating cognition. Those targets that show promise for pharmacologic focus include the dopamine receptors (especially D1) in the prefrontal cortex (PFC), the serotonin receptors in the PFC and anterior cingulate cortex, the glutamatergic excitatory synapse, the acetylcholine nicotinic receptors in the hippocampus, the acetylcholine muscarinic receptors, and the brain γ-aminobutyric acid (GABA) system. Once developed and tested, the effective compounds will be valuable for the treatment of the symptom domains of cognitive dysfunction and negative symptoms.

UR - http://www.scopus.com/inward/record.url?scp=33748529631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748529631&partnerID=8YFLogxK

M3 - Article

C2 - 16965183

AN - SCOPUS:33748529631

VL - 67

SP - 9

EP - 13

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 9

ER -